Second such recall this year by pharma giant that acquired Ranbaxy earlier this year
Sun Pharmaceutical Industries Ltd has voluntarily recalled 200 vials of its cancer drug, gemcitabine, in the United States. This was because of lack of assurance of sterility of the vials, informed US Food and Drug Administration (USFDA) on Thursday.
The drug was manufactured by the pharma’s giant’s Gujarat unit, Caraco Pharmaceutical Laboratories Ltd, informs the USFDA website.
The recall was initiated in April and USFDA classified the drug as Class II, which means its use may cause temporary or medical reversible adverse health consequences.
This is the second time the company has recalled its product in 2014. Earlier, Sun Pharma initiated voluntary recall of around 2,500 bottles of generic version of diabetes drug, Glumetza.
In April, Sun Pharma had announced the acquisition of Ranbaxy Laboratories Ltd. Ranbaxy, which is one of the biggest generic drug makers of India, had recently been questioned by the US authorities for not meeting “good manufacturing practices’ norms.
The year has been a happening one for Sun Pharma, which also settled a pact with Novartis Pharmaceutical Corporation, for its cancer drug Gleevec. The company can launch a generic version of medicine in US from 2016.
We are a voice to you; you have been a support to us. Together we build journalism that is independent, credible and fearless. You can further help us by making a donation. This will mean a lot for our ability to bring you news, perspectives and analysis from the ground so that we can make change together.
.png)
Comments are moderated and will be published only after the site moderator’s approval. Please use a genuine email ID and provide your name. Selected comments may also be used in the ‘Letters’ section of the Down To Earth print edition.